Pharma Stocks
-
HSI Rises 95 Points Led by Pharma Stocks; CSPC Surges Nearly 14% AASTOCKS Financial News
You expressly agree that the use of this app/website is at your sole risk. AASTOCKS.com Limited, HKEx Information Services Limited,…
Read More » -
Could Buying Eli Lilly Today Set You Up for Life?
If you are interested in buying Eli Lilly (LLY 1.90%) today, it is most likely because of the success of…
Read More » -
0503.HK Lansen Pharma HKSE +40.94% pre-market 27 Mar 2026: outlook
The 0503.HK stock surged in pre-market trade on 27 Mar 2026, rising to HKD 1.79 after a +40.94% jump on…
Read More » -
A Steady Leader in Pharmaceuticals with Strong Diagnostics and Oncology Focu
Roche Holding AG (ISIN: CH0012032048), the Swiss pharmaceutical giant, offers North American investors exposure to innovative oncology drugs, diagnostics, and…
Read More » -
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical…
Read More » -
Driven by leading pharmaceutical companies’ performance and the easing of tensions in the Middle East, the largest Hang Seng Pharma ETF Huaxia (159892) rose by 1.77%, while the HK Connect Healthcare ETF Huaxia (520510) garnered significant investor attent
Gelonghui, March 26 | Today, the healthcare sector of Hong Kong stocks rebounded. The HShares Healthcare ETF (159892) managed by…
Read More » -
After Hours Top Loser: NWRN.SW Newron Pharmaceuticals (SIX) 25 Mar 2026: Oversold
NWRN.SW stock fell to CHF 14.64 in after-hours trade on 25 Mar 2026, marking a short-term downshift as investors digest…
Read More » -
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history.…
Read More » -
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following LUCIDITY Phase 3 Enrollment Completion
Amylyx Pharmaceuticals recently completed enrollment in its pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, a 16-week, randomized,…
Read More » -
Recordati S.p.A. stock faces pressure amid rare disease drug pipeline scrutiny and European pharma s
The Recordati S.p.A. stock (ISIN: IT0003828271) trades on the Milan Stock Exchange in euros, showing limited movement in recent sessions…
Read More »